SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets brain lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests the safety of a drug called glofitamab, given after a pre-treatment with obinutuzumab, for people with central nervous system (CNS) lymphoma. The study enrolls 20 adults with primary or secondary CNS lymphoma. The goal is to see if this combination is…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for hard-to-treat brain cancer: drug duo targets relapsed lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, zanubrutinib and pemetrexed, in people whose central nervous system lymphoma has returned or not responded to prior treatment. The goal is to see if this approach can shrink tumors and control the disease. About 15 participants will re…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Engineered immune cells take on hard-to-treat brain cancer in early trial
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. About 12 adults will receive different doses to find the safest one. The therapy uses the pat…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for High-Risk lymphoma: maintenance drug aims to prevent relapse
Disease control Recruiting nowThis study tests whether the drug acalabrutinib, taken after cell therapy (like stem cell transplant or CAR T-cells), can help prevent relapse in patients with very high-risk large B-cell lymphoma. About 24 adults aged 18-70 will participate. The goal is to see if the drug is tol…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug cocktail takes on recurrent brain cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is t…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Brain radiation's hidden toll: new study tracks memory loss in blood cancer patients
Knowledge-focused Recruiting nowThis study follows 100 adults with blood cancers who receive whole brain radiation therapy to see how it affects their memory and thinking skills. Researchers will test cognitive function over time using standard assessments. The goal is to better understand the side effects of t…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 13, 2026 16:04 UTC